Literature DB >> 28574596

G protein-coupled receptor 84 controls osteoclastogenesis through inhibition of NF-κB and MAPK signaling pathways.

Ji-Wan Park1, Hye-Jin Yoon1, Woo Youl Kang1, Seungil Cho1, Sook Jin Seong1, Hae Won Lee1, Young-Ran Yoon1, Hyun-Ju Kim1.   

Abstract

GPR84, a member of the G protein-coupled receptor family, is found predominantly in immune cells, such as macrophages, and functions as a pivotal modulator of inflammatory responses. In this study, we investigated the role of GPR84 in receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast differentiation. Our microarray data showed that GPR84 was significantly downregulated in osteoclasts compared to in their precursors, macrophages. The overexpression of GPR84 in bone marrow-derived macrophages suppressed the formation of multinucleated osteoclasts without affecting precursor proliferation. In addition, GPR84 overexpression attenuated the induction of c-Fos and nuclear factor of activated T cells, cytoplasmic 1 (NFATc1), which are transcription factors that are critical for osteoclastogenesis. Furthermore, knockdown of GPR84 using a small hairpin RNA promoted RANKL-mediated osteoclast differentiation and gene expression of osteoclastogenic markers. Mechanistically, GPR84 overexpression blocked RANKL-stimulated phosphorylation of IκBα and three MAPKs, JNK, ERK, and p38. GPR84 also suppressed NF-κB transcriptional activity mediated by RANKL. Conversely, GPR84 knockdown enhanced RANKL-induced activation of IκBα and the three MAPKs. Collectively, our results revealed that GPR84 functions as a negative regulator of osteoclastogenesis, suggesting that it may be a potential therapeutic target for osteoclast-mediated bone-destructive diseases.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  GPR84; NF-κB; NFATc1; c-Fos; osteoclastogenesis

Mesh:

Substances:

Year:  2017        PMID: 28574596     DOI: 10.1002/jcp.26035

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  3 in total

1.  Magnolol prevents ovariectomy‑induced bone loss by suppressing osteoclastogenesis via inhibition of the nuclear factor‑κB and mitogen‑activated protein kinase pathways.

Authors:  Wen-Yong Fei; Qiang Huo; Pei-Qing Zhao; Long-Juan Qin; Tao Li
Journal:  Int J Mol Med       Date:  2019-02-18       Impact factor: 4.101

2.  MyD88 mediates colorectal cancer cell proliferation, migration and invasion via NF‑κB/AP‑1 signaling pathway.

Authors:  Guangwei Zhu; Zhibin Cheng; Yongjian Huang; Wei Zheng; Shugang Yang; Chunlin Lin; Jianxin Ye
Journal:  Int J Mol Med       Date:  2019-10-31       Impact factor: 4.101

3.  Identification of recurrent variants implicated in disease in bicuspid aortic valve patients through whole-exome sequencing.

Authors:  Shasha Chen; Qinchun Jin; Shiqiang Hou; Mingfei Li; Yuan Zhang; Lihua Guan; Wenzhi Pan; Junbo Ge; Daxin Zhou
Journal:  Hum Genomics       Date:  2022-09-07       Impact factor: 6.481

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.